Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herman Waldmann

Showing results (121-130 of 153) with videos related to

Pageof 16
Sort By:
Blood|July 20, 2002
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Jeanette Lundin, Eva Kimby, Magnus Björkholm, et al.
Plos One|November 26, 2009
Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic targetSylvaine You, Lynn Poulton, Steve Cobbold, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|June 16, 2004
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitisConor C Murphy, Kathrin Greiner, Jarka Plskova, et al.
Blood|July 19, 2003
Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantationSuparno Chakrabarti, Donald W Milligan, Deenan Pillay, et al.
Frontiers in Immunology|June 6, 2018
Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune DiabetesRobert A Benson, Fabien Garcon, Asha Recino, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2009
Infectious tolerance via the consumption of essential amino acids and mTOR signalingStephen P Cobbold, Elizabeth Adams, Claire A Farquhar, et al.
The Journal of Clinical Investigation|February 25, 2010
Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in miceMichio Tomura, Tetsuya Honda, Hideaki Tanizaki, et al.
Molecular Genetics and Metabolism Reports|November 30, 2016
Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe diseaseBaodong Sun, Suhrad G Banugaria, Sean N Prater, et al.
Journal of Neurology|July 27, 2005
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapyAlasdair J Coles, Amanda Cox, Emmanuelle Le Page, et al.
Journal of Clinical Pharmacology|February 12, 2010
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetesGeoff Hale, Peppy Rebello, Ibrahim Al Bakir, et al.
Pageof 16

Showing results (121-130 of 153) with videos related to

Sort By:
Pageof 16
Blood|July 20, 2002
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Jeanette Lundin, Eva Kimby, Magnus Björkholm, et al.
Plos One|November 26, 2009
Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic targetSylvaine You, Lynn Poulton, Steve Cobbold, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|June 16, 2004
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitisConor C Murphy, Kathrin Greiner, Jarka Plskova, et al.
Blood|July 19, 2003
Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantationSuparno Chakrabarti, Donald W Milligan, Deenan Pillay, et al.
Frontiers in Immunology|June 6, 2018
Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune DiabetesRobert A Benson, Fabien Garcon, Asha Recino, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2009
Infectious tolerance via the consumption of essential amino acids and mTOR signalingStephen P Cobbold, Elizabeth Adams, Claire A Farquhar, et al.
The Journal of Clinical Investigation|February 25, 2010
Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in miceMichio Tomura, Tetsuya Honda, Hideaki Tanizaki, et al.
Molecular Genetics and Metabolism Reports|November 30, 2016
Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe diseaseBaodong Sun, Suhrad G Banugaria, Sean N Prater, et al.
Journal of Neurology|July 27, 2005
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapyAlasdair J Coles, Amanda Cox, Emmanuelle Le Page, et al.
Journal of Clinical Pharmacology|February 12, 2010
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetesGeoff Hale, Peppy Rebello, Ibrahim Al Bakir, et al.
Pageof 16